Skip to main content

Apricus Biosciences Value Stock - Dividend - Research Selection

Apricus Biosciences

ISIN: US03832V3078, WKN: A2AT45

Market price date: 30.11.-0001
Market price: 0,00 USD

Apricus Biosciences Fundamental data and company key figures of the share

Annual reports in USD
Key figures 13-03-2018
Cash flow
Net operating cash flow -19.305.000
Capital Expenditures 8.126.000
Free cash flow -19.305.000
Balance sheet
Total Equity -7.000
Liabilities & Shareholders equity 11.096.000
Income statement
Net income -51.255.000
Eps (diluted) -2,520
Diluted shares outstanding 15.220.000
Net sales/revenue 375.000

Fundamental ratios calculated on: 30-11--0001

Key figures 30-11--0001
Cash flow
P/C 0,00
P/FC 0,00
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization64.228.400,00 USD
Raw Data Source
Stock Split

Description of the company

Apricus Biosciences, Inc. is in the pharmaceutical industry primarily focusing on research and development using its drug delivery technology called NexACT. The Company is actively engaged in acquiring companies and in-licensing drugs that will complement its product portfolio.The Company´s pipeline of approved and late stage NexACT based product candidates includes Vitaros, which is approved in Canada for the treatment of erectile dysfunction, Femprox for female sexual arousal disorder, MycoVa for onychomycosis excluding tinea pedis (nail fungal infection), RayVa for Raynaud´s Syndrome and PrevOnco for liver cancer. The Company´s pipeline of late stage preclinical products includes Nupen for post-chemotherapy recovery of Neutrophil. In June, 2011, the Company sold Bio-Quant, Inc. (Bio-Quant). On December 29, 2011, the Company acquired Topotarget USA, Inc. In April 2013, the Company announced the sale of Totect (dexrazoxane HCl), and NitroMist (nitroglycerin sublingual aerosol).

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,